One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry.
Adult
Antibodies, Monoclonal, Humanized
/ economics
Antirheumatic Agents
/ economics
Arthritis, Rheumatoid
/ drug therapy
Biological Factors
/ therapeutic use
Biological Products
/ economics
Biological Therapy
/ economics
Cost-Benefit Analysis
Etanercept
/ economics
Female
Health Care Costs
/ statistics & numerical data
Health Expenditures
Humans
Male
Middle Aged
Morocco
Rituximab
/ economics
Annual direct cost
Biological therapy
RBSMR registry
Rheumatoid arthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
12
10
2020
accepted:
24
11
2020
pubmed:
3
1
2021
medline:
1
12
2021
entrez:
2
1
2021
Statut:
ppublish
Résumé
The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann-Whitney and Kruskal-Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472-€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.
Identifiants
pubmed: 33386900
doi: 10.1007/s00296-020-04762-7
pii: 10.1007/s00296-020-04762-7
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
Biological Factors
0
Biological Products
0
Rituximab
4F4X42SYQ6
tocilizumab
I031V2H011
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787-793Références
Benbouazza K, Benchekroun B, Rkain H, Amine B, Bzami F, Benbrahim L, Atouf O, Essakalli M, Abouqal R, Dougados M, Hajjaj-Hassouni N (2011) Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up study. BMC Musculoskel Disord 12:266. https://doi.org/10.1186/1471-2474-12-266
doi: 10.1186/1471-2474-12-266
Badsha H, Fathi NA, Hamoud H, Hajjaj-Hassouni N et al (2009) Profile of patients with rheumatoid arthritis in rarely-reported locations: North Africa. Ann Rheum Dis 68(Suppl3):352
Ibn Yacoub Y, Amine B, Laatiris A, Wafki F, Znat F, Hajjaj-Hassouni N (2012) Fatigue and severity of rheumatoid arthritis in Moroccan patients. Rheumatol Int 32:1901–1907. https://doi.org/10.1007/s00296-011-1876-0
doi: 10.1007/s00296-011-1876-0
pubmed: 21448644
Fazal SA, Khan M, Nishi SE, Alam F, Zarin N, Bari MT, Ashraf GM (2018) A clinical update and global economic burden of rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets 18(2):98–109. https://doi.org/10.2174/1871530317666171114122417
doi: 10.2174/1871530317666171114122417
pubmed: 29141572
Rkain H, Allali F, Jroundi I, Hajjaj-Hassouni N (2006) Socioeconomic impact of rheumatoid arthritis in Morocco. Joint Bone Spine 73(3):278–283. https://doi.org/10.1016/j.jbspin.2005.03.021
doi: 10.1016/j.jbspin.2005.03.021
pubmed: 16376598
Ghabri S, Lam L, Bocquet F, Spath HM (2020) Systematic literature review of economic evaluations of biological treatment sequences for patients with moderate to severe rheumatoid arthritis previously treated with disease-modifying anti-rheumatic drugs. Pharmaco Econ 38(5):459–471. https://doi.org/10.1007/s40273-020-00887-6
doi: 10.1007/s40273-020-00887-6
Law ST, Taylor PC (2019) Role of biological agents in treatment of rheumatoid arthritis. Pharmacol Res 150:104497. https://doi.org/10.1016/j.phrs.2019.104497
doi: 10.1016/j.phrs.2019.104497
pubmed: 31629903
Pisetsky DS (2017) Advances in the treatment of rheumatoid arthritis: costs and challenges. North Carolina Med J 78(5):337–340. https://doi.org/10.18043/ncm.78.5.337
doi: 10.18043/ncm.78.5.337
Yassine A, Hangouche AJ, El Malhouf N, Maarouf S, Taoufik J (2020) Assessment of the medical expenditure of the basic health insurance in Morocco. Pan Afr Med J 14(35):115. https://doi.org/10.11604/pamj.2020.35.115.13076
doi: 10.11604/pamj.2020.35.115.13076
Yassine A, El Hangouche AJ, Malhouf NE, Maarouf S, Taoufik J (2018) Les caractéristiques de la population couverte par le régime de l’assurance maladie obligatoire au Maroc [The characteristics of the population covered by Compulsory Health Insurance (CMI) in Morocco]. Pan Afr Med J 30:266. https://doi.org/10.11604/pamj.2018.30.266.13209
doi: 10.11604/pamj.2018.30.266.13209
pubmed: 30637051
pmcid: 6317406
Smolen JS, Landewé R, Bijlsma J et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655
doi: 10.1136/annrheumdis-2019-216655
Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, Fautrel B, Mariette X, Nayral N, Richez C, Saraux A, Thibaud G, Wendling D, Gossec L, Combe B (2019) Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 86(2):135–150. https://doi.org/10.1016/j.jbspin.2018.10.002
doi: 10.1016/j.jbspin.2018.10.002
pubmed: 30315988
Niamane R, Bahiri R, Bouchti I et al (2014) Recommandations de la Société Marocaine de Rhumatologie pour la prise en charge de la polyarthrite rhumatoïde : mise à jour du référentiel de 2011. Rev Mar Rhum 2014(30):3–13
Sokka T, Kautiainen H, Pincus T et al (2010) Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 12(2):R42. https://doi.org/10.1186/ar2951
doi: 10.1186/ar2951
pubmed: 20226018
pmcid: 2888189
Verhoef LM, Bos D, van den Ende C, van den Hoogen F, Fautrel B, Hulscher ME, Kievit W, den Broeder AA (2019) Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study. Scand J Rheumatol 48(6):439–447. https://doi.org/10.1080/03009742.2019.1613674
doi: 10.1080/03009742.2019.1613674
pubmed: 31220991
Pazmino S, Boonen A, Stouten V, De Cock D, Joly J, Van der Elst K, Westhovens R, Verschueren P (2020) Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. Ann Rheum Dis 79(5):556–565. https://doi.org/10.1136/annrheumdis-2019-216874
doi: 10.1136/annrheumdis-2019-216874
pubmed: 32241795
Patel A, Heslin M, Scott DL, Stringer D, Birrell F, Ibrahim F (2020) Cost-effectiveness of combination disease-modifying antirheumatic drugs versus tumor necrosis factor inhibitors in active rheumatoid arthritis: a pragmatic, randomized. Multicenter Trial Arthritis Care Res 72(3):334–342. https://doi.org/10.1002/acr.23830
doi: 10.1002/acr.23830
Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, Gómez S, de Andrés-Nogales F, Casado MA, Oyagüez I (2020) Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain. Clin Rheumatol 39(10):2919–2930. https://doi.org/10.1007/s10067-020-05087-3
doi: 10.1007/s10067-020-05087-3
pubmed: 32303858
pmcid: 7497326
Drosos AA, Pelechas E, Kaltsonoudis E, Voulgari PV (2020) Therapeutic options and cost-effectiveness for rheumatoid arthritis treatment. Curr Rheumatol Rep 22(8):44. https://doi.org/10.1007/s11926-020-00921-8
doi: 10.1007/s11926-020-00921-8
pubmed: 32591916
Martínez-López-de-Castro, N., Álvarez-Payero, M., Samartín-Ucha, M et al (2020) Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. Clin Exp Rheumatol (advance online publication)
Gu T, Mutebi A, Stolshek BS, Tan H (2018) Cost of biologic treatment persistence or switching in rheumatoid arthritis. Am J Manage Care 24(8):SP338–SP345
Best JH, Vlad SC, Pei J (2020) Comparative cost per response for 4 clinical endpoints with tocilizumab monotherapy vs adalimumab monotherapy in a head-to-head randomized double-blind superiority trial (ADACTA) in patients with rheumatoid arthritis. Rheumatol Ther 7(1):165–171. https://doi.org/10.1007/s40744-019-00191-6
doi: 10.1007/s40744-019-00191-6
pubmed: 31907758
pmcid: 7021858
Ohinmaa AE, Thanh NX, Barnabe C, Martin L, Russell AS, Barr SG, Maksymowych WP (2014) Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents. Arthritis Care Res (Hoboken) 66(9):1319–1327. https://doi.org/10.1002/acr.22293
doi: 10.1002/acr.22293
González Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, Plasencia C, Gayá F, Herrero A, Balsa A (2019) Cost evolution of biological drugs in rheumatoid arthritis patients in a tertiary hospital: influential factors on price. Reumatol Clin S1699–258X(19):30162–30167. https://doi.org/10.1016/j.reuma.2019.10.004
doi: 10.1016/j.reuma.2019.10.004
Benchérifa S, Amine B, Elbinoune I et al (2019) Radiographic axial versus nonradiographic axial spondyloarthritis: comparison of the disease activity parameters and the disease activity and functional scores: RBSMR study. Intern J Clin Rheumatol 14:282
Kherrab A, Chitachen H, Chergaoui I et al (2020) Utilisation des AINS et des antalgiques chez les patients ayant une spondyloarthrite sous biothérapie. Données du registre de biothérapiede la Société Marocaine de rhumatologie (RBSMR). Revue du Rhumatisme 87(5):374–379. https://doi.org/10.1016/j.rhum.2020.07.003
doi: 10.1016/j.rhum.2020.07.003
Hmamouchi I, Abouqal R, Achemlal L, Allali F, Bahiri R, El Bouchti I et al (2019) The Moroccan registry of biological therapies in rheumatic diseases (RBSMR): methods and preliminaries results. Rev Mar Rhum 49:32–37
High Commission for Planning of Morocco (2020) Keys figures. https://www.hcp.ma/ . Accessed 05 Nov 2020
High Commission for Planning of Morocco (2020) La situation économique nationale en 2019. https://www.hcp.ma/ . Accessed 05 Nov 2020
Sugiyama N, Kawahito Y, Fujii T, Atsumi T, Murata T, Morishima Y, Fukuma Y (2016) Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data. Clin Ther 38(6):1359-1375.e1. https://doi.org/10.1016/j.clinthera.2016.03.022
doi: 10.1016/j.clinthera.2016.03.022
pubmed: 27101816
Nolla JM, Martín E, Llamas P, Manero J, Rodríguez de la Serna A, Fernández-Miera MF, Rodríguez M, López JM, Ivanova A, Aragón B (2017) An estimate of the cost of administering intravenous biological agents in Spanish day hospitals. Ther Clin Risk Manag 14(13):325–334. https://doi.org/10.2147/TCRM.S112062
doi: 10.2147/TCRM.S112062
Naqvi AA, Hassali MA, Naqvi S, Kachela B, Khan I (2020) Estimation of direct cost of managing rheumatoid arthritis treatment to Pakistani patients using real-world follow-up data. Intern J Rheumat Dis 23(3):325–333. https://doi.org/10.1111/1756-185X.13776
doi: 10.1111/1756-185X.13776
Souliotis K, Golna C, Kani C, Nikolaidi S, Boumpas D (2019) Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece. PLoS ONE 14(12):e0226287. https://doi.org/10.1371/journal.pone.0226287
doi: 10.1371/journal.pone.0226287
pubmed: 31830144
pmcid: 6907839
Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A (2013) Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database. Rheumatol Int 33(10):2577–2584. https://doi.org/10.1007/s00296-013-2782-4
doi: 10.1007/s00296-013-2782-4
pubmed: 23708559
Eddaoudi M, Rostom S, Hmamouchi I et al (2020) The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. Research Square. https://doi.org/10.21203/rs.3.rs-51813/v1
doi: 10.21203/rs.3.rs-51813/v1